Disc Medicine (IRON) Other Accumulated Expenses (2020 - 2026)
Disc Medicine (IRON) reported Other Accumulated Expenses of $870000.0 for Q1 2026, up 71.6% year-over-year from $507000.0 in Q1 2025, and up 23.4% quarter-over-quarter from $705000.0 in Q4 2025.
Disc Medicine (IRON) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has 7 years of Other Accumulated Expenses data on file, last reported at $870000.0 in Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $870000.0, up 71.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $870000.0 (up 71.6% YoY), and the FY2025 annual result was $705000.0, up 98.59% from the prior year.
- Other Accumulated Expenses climbed to $870000.0 in Q1 2026 per IRON's latest filing, from $705000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $870000.0 in Q1 2026 and troughed at $52000.0 in Q4 2023.
- A 5-year average of $390428.6 and a median of $291000.0 in 2023 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses surged 880.95% in 2022, then sank 74.76% in 2023.
- A 5-year view of Other Accumulated Expenses shows it stood at $206000.0 in 2022, then slumped by 74.76% to $52000.0 in 2023, then surged by 582.69% to $355000.0 in 2024, then surged by 98.59% to $705000.0 in 2025, then advanced by 23.4% to $870000.0 in 2026.
- Business Quant data shows IRON's Other Accumulated Expenses at $870000.0 in Q1 2026, $705000.0 in Q4 2025, and $749000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Disc Medicine | 2.62 Bn | 1.89 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 870,000.00 |
| Dec 31, 2025 | 705,000.00 |
| Sep 30, 2025 | 749,000.00 |
| Jun 30, 2025 | 810,000.00 |
| Mar 31, 2025 | 507,000.00 |
| Dec 31, 2024 | 355,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 188,000.00 |
| Mar 31, 2024 | 199,000.00 |
| Dec 31, 2023 | 52,000.00 |
| Sep 30, 2023 | 54,000.00 |
| Jun 30, 2023 | 189,000.00 |
| Mar 31, 2023 | 345,000.00 |
| Dec 31, 2022 | 206,000.00 |
| Dec 31, 2021 | 21,000.00 |
| Sep 30, 2021 | 16,000.00 |
| Jun 30, 2021 | 147,000.00 |
| Mar 31, 2021 | 87,000.00 |
| Dec 31, 2020 | 46,000.00 |